Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Sangui Patent for Production of Artificial Oxygen Carriers Granted

October 17, 2012

WITTEN, Germany, October 17, 2012 /PRNewswire/ –

As expected and previously indicated, the European Patent Office has granted a patent
based on Sangui’s application (EP 01 945 245): “Mammalian hemoglobin compatible with blood
plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen
carriers, production and use thereof”. The grant is effective today, October 17, 2012,
subsequent to its official publication by the Patent Office.

Sangui BioTech International, Inc. (“SGBI”) is a holding company the shares of which
are being traded on the OTCQB marketplace (http://www.otcmarkets.com: SGBI) and the OTC
market of Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access
to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a
ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations,
contain projections of results of operation or financial condition or state other
“forward-looking” information. These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual results to differ materially
from those contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important factors that may
cause actual results to differ from projections include, among many others, the ability of
the Company to raise sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and
variations of such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes no obligation
to update publicly any forward-looking statements, whether as a result of new information,
future events or otherwise.

        For more information please contact:
        Joachim Fleing
        Phone: +49-(179)-7963472
        Fax: +49-(2302)-915191
        e-mail: fleing@sangui.de

SOURCE Sangui Bio Tech International Inc.


Source: PR Newswire